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A 55-year-old woman with variant angina was hospitalized for cardiopulmonary arrest because of pulseless
electrical activity (PEA). Despite intensive postresuscitation drug therapy, another episode of angina
occurred, with complete atrioventricular block and PEA. There was no conﬁrmed ventricular ﬁbrillation or
ventricular tachycardia. Coronary arteriography did not show signiﬁcant stenosis, and acetylcholine-loading
test was positive. The patient was diagnosed with coronary spastic angina, and a pacemaker was implanted
to stabilize hemodynamics during attacks. The pacemaker settings required some ingenuity: a high output
was selected to avert pacing failure, and a rate drop response setting was selected to ensure efﬁcient pacing.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Coronary spastic angina can lead to fatal arrhythmias and
sudden death. The cornerstone of treatment is drug therapy based
on calcium channel blockers, but recurrence is not uncommon.
Non-pharmacological therapies have not been found to prevent
recurrence involving fatal arrhythmias or pulseless electrical
activity (PEA). This is a case report of a patient with coronary
spastic angina who developed complete atrioventricular block
and PEA, and who underwent implantation of a permanent
pacemaker after resuscitation.2. Case report
At 7:00 PM one evening in December 2010, a 55-year-old
woman was brought by ambulance because of cardiopulmonary
arrest after an episode of chest pain at her home. She was
diagnosed with PEA, and cardiopulmonary resuscitation by chest
compression was continued for 20 min. She was resuscitated and
transported to our hospital. Family history included the death of
her father from myocardial infarction. She had a 32-year smoking
history of 20 cigarettes a day, starting at the age of 20 years, butrt Rhythm Society. Published by E
: þ81 47 458 7047.
. Kamishima).she had quit smoking 3 years previously. Three years ago, the
patient had fainted for 1 min after chest pains early in
the morning. ECG showed transient ST segment elevation in the
inferior wall leads and conﬁrmed sinus bradycardia. Coronary
arteriography did not show signiﬁcant stenosis, and left ventri-
culography showed normal left ventricular systolic function. The
patient was diagnosed with variant angina and was started on
oral therapy with benidipine hydrochloride (6 mg once a day),
isosorbide mononitrate (20 mg twice a day), and nicorandil (5 mg
thrice a day). There was no conﬁrmed ventricular ﬁbrillation or
ventricular tachycardia.
The patient was 147 cm tall and obese (body mass index,
25.9 kg/m2). Blood pressure was 138/85 mmHg, with a regular
pulse of 104 bpm. Her level of consciousness was Glasgow Coma
Scale (GCS)-3, and pupils were 3/3 mm, without light reﬂexes.
Breath sounds were clear, with no discernible cardiac murmurs
and no lower extremity edema. Other than prolonged disturbed
consciousness, there were no speciﬁc abnormal ﬁndings.
Laboratory test results were as follows: WBC, 6140/mL; Hb,
14.3 g/dL; Plt, 233,000/mL; TP, 6.5 g/dL; Alb, 3.6 g/dL; AST,
101 IU/L; ALT, 55 IU/L; CK, 58 IU/L; Cr, 0.82 mg/dL; UA, 6.5 mg/
dL; Na, 138 mEq/L; K, 4.2 mEq/L; troponin I, 0.04 ng/mL; BNP,
40 pg/mL; T.chol, 183 mg/dL; TG, 130 mg/dL; HDL, 59 mg/dL;
LDL, 106 mg/dL; BS, 85 mg/dL; HbA1c, 5.1%; and D-dimer,
0.98 mg/mL. AST elevation was assumed to be the result
of circulatory failure associated with cardiopulmonary arrest.lsevier B.V. All rights reserved.
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segment depression and negative T waves in leads II, III, and aVF.
Plain chest X-ray showed a cardiothoracic ratio of 40%, with no
congestive ﬁndings. Plain CT showed no obvious ﬁndings indica-
tive of cerebrovascular disease or aortic disease. Echocardiogra-
phy showed good left ventricular systolic function, with no
evidence of wall motion abnormalities or underlying heartFig. 1. Monitor ECG during angina attack (a) ECG in the normal range at 4:25 AM. (b) Ch
ineffective, and intravenous isosorbide nitrate is therefore started. (c) Bradycardia with
atropine sulfate is therefore administered. (d) Patient loses consciousness at 4:55 AM an
administered. (e) Heart beat resumes at 5:00 AM. ECG shows ST segment elevation. (f)
depression.disease such as cardiomyopathy and valvulopathy. Based on the
ﬁndings up to that point in time, the attacks were suspected as
variant angina, and treatment was started with continuous
intravenous heparin (10,000 units/day) and nicorandil (48 mg/
day) infusions. The patient regained consciousness on Day 2. Oral
treatment with benidipine, isosorbide mononitrate, and nicoran-
dil was resumed on Day 3, and the patient began to eat. Theest pains appear, with ST segment elevation, at 4:30 AM. Sublingual nitroglycerin is
heart rate of 37 bpm due to complete atrioventricular block occurs at 4:40 AM, and
d goes into cardiopulmonary arrest; chest compression is started and epinephrine
At 5:25 AM, ST segment elevation disappears, followed by persistent ST segment
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quently stabilized.
However, she had an attack on Day 7. The ECG monitor was
normal until 4:25 AM (Fig. 1a). ST segment elevation was evident,
and the patient experienced chest pain at 4:30 AM (Fig. 1b). ST
segment elevations were seen in leads II, III, and aVF on the
12-lead ECG. As sublingual nitroglycerin was ineffective, intrave-
nous isosorbide nitrate was started. Bradycardia with a heart rate
of 37 bpm because of complete atrioventricular block occurred at
4:40 AM (Fig. 1c), and atropine sulfate was therefore adminis-
tered. At 4:55 AM, the patient lost consciousness and went into
cardiopulmonary arrest because of PEA. Chest compression was
started, and epinephrine was administered (Fig. 1d). The patient’s
heart started beating again at 5:00 AM, with the ECG showing ST
segment elevation (Fig. 1e). The patient regained consciousness
and the ST segment elevation disappeared at 5:25 AM, followed
by persistent ST segment depression (Fig. 1f). The cause of
cardiopulmonary arrest was determined to be bradycardia and
PEA associated with variant angina. Ventricular ﬁbrillation or
ventricular tachycardia was not detected. The patient was started
on continuous intravenous infusions of isosorbide nitrate, and
treatment with oral nicorandil was resumed. Drug therapy was
enhanced with the addition of oral benidipine, as well as diltia-
zem (30 mg twice a day) and pitavastatin (2 mg once a day).
The patient was also administered magnesium oxide orallyFig. 2. Coronary arteriography during acetylcholine loading and OCT ﬁndings (a) Left co
medication was continued. This resulted in obstruction of the anterior descending bran
episode of chest pain, and the ECG shows ST segment elevation at the precordial lead.
performed after the attack had subsided shows that the constriction has resolved. (c)
right coronary artery. This resulted in chest pain and complete atrioventricular block.
decrease in the short term. (d) The constriction subsided after intracoronary infusion o
areas where no coronary artery spasms had occurred. (f) Pronounced thickening is foun
coronary artery spasms resulted in obstruction. OCT: Optical Coherence Tomography.(330 mg thrice a day) for regular bowel movements, and the
magnesium was expected to help control coronary artery spasms.
The patient’s decreased blood pressure precluded any further
dose increases.
Coronary arteriography was performed after optimization of
drug therapy. Low-dose acetylcholine loading was performed
while the patient continued her oral medication. A pacing lead
was inserted into the right ventricle in case of bradycardia, and
back-up pacing was performed at 50 ppm (paces per minute) in
VVI mode. Intracoronary infusion of 10 mg acetylcholine into the
left coronary artery resulted in obstruction of the anterior
descending branch (segment 7), and 90% constriction in the
diagonal branch (segment 9) and circumﬂex branch (segment
13) (Fig. 2a). ECG showed ST segment elevation in the precordial
lead, resulting in chest symptoms. Pacing in VVI mode was
activated because of bradycardia induced by complete atrioven-
tricular block. The pacing threshold was measured before the
coronary artery spasms had subsided. The pacing threshold was
r1 V, and the pacing was continuously captured at 3 V in VVI 90
with a stable hemodynamic condition of 110/60 mmHg, until the
coronary artery spasms subsided.
Arteriography performed after the attack had subsided showed
that the constriction had resolved (Fig. 2b). Subsequent intracor-
onary infusion of 10 mg acetylcholine into the right coronary
artery resulted in 99% constriction in segment 3 (Fig. 2c). ECGronary arteriography after intracoronary infusion of 10 mg acetylcholine while oral
ch and 90% constriction of the circumﬂex branch. The patient experienced another
A pacing lead was inserted in the right ventricle. (b) Left coronary arteriography
Intracoronary infusion of 10 mg acetylcholine 10 mg resulted in obstruction of the
Right ventricular pacing was performed. The pacing threshold was r1 V, with no
f nitroglycerin. (e) OCT shows that the three-layered vascular structure is intact in
d around nearly the entire circumference of the media and intima in areas where
K. Kamishima et al. / Journal of Arrhythmia 29 (2013) 275–280278showed ST segment elevation and complete AV block, resulting in
chest symptoms. The pacing threshold was similarly kept within
1 V, and the pacing was continuously captured at 3 V in VVI 90
with a stable hemodynamic condition. Under these conditions,
concomitant pacing therapy did not result in hemodynamic
disruption, at least in the short term. The induction of coronary
artery spasms did not lead to ventricular ﬁbrillation or ventricular
tachycardia until the spontaneous reduction of coronary spasms.
Intracoronary infusion of nitroglycerin revealed no signiﬁcant
coronary stenosis (Fig. 2d). The state of the right coronary artery
walls was assessed by optical coherence tomography (OCT)
following coronary artery dilatation with nitroglycerin. An Ima-
geWires (Lightlab Imaging Inc., Westford, MA, USA) was inserted,
segment 2 was occluded with a balloon, and red blood cells were
washed out by infusion of Ringer’s solution at 0.5 mL/s. In the
areas of segment 2 that appeared to be nearly normal on
angiography, OCT showed that the normal three-layered structure
of the vessel wall was intact (Fig. 2e). Meanwhile, pronounced
intimal and medial thickening was observed in segment 3, where
the coronary artery spasms had been induced (Fig. 2f). The cause
of variant angina with ST segment elevation at rest thus appeared
to be coronary spastic angina involving multiple vessel spasms.
The patient had experienced cardiopulmonary arrest because
of PEA and bradycardia at least twice while on oral treatment for
variant angina, but neither ventricular ﬁbrillation nor ventricular
tachycardia was apparent. Spontaneous attacks occurred despite
the use of an oral calcium blocker, and low-dose acetylcholine
loading induced coronary artery spasms even after oral treatment
with two concomitant calcium blockers and nitrates. Because
hemodynamics were stable and there was no conﬁrmed decrease
in pacing threshold, we concluded that pacing therapy would be
an effective way to manage bradycardia during attacks, and a
permanent DDD pacemaker (Adapta L ADDR1s, Medtronic Inc.,
Minneapolis, MN, USA) was implanted. Pacing leads were
implanted in the right ventricular apex and right atrial
appendage. For the pacemaker settings, the ventricular output
was set to 7.5 V, taking into account potential increases in
stimulation threshold due to myocardial ischemia. Because ven-
tricular pacing under normal conditions shortens battery life, a
rate drop response setting was used, which ensured that pacing
was curbed during normal conditions and activated only when
the heart rate fell during attacks. The pacemaker settings were as
shown below.
Adapta L ADDR1 (Medtronic); Atrial lead, 555445 (Medtronic);
Ventricular lead, 504552 (Medtronic).
AAI o-4 DDD (MVP: Managed Ventricular Pacing); lower
rate, 35; upper rate, 130; paced AVD, 150 ms; sensed AVD, 120 ms
Atrial Amplitude, 3.5 V; Pulse width, 0.40 ms; Sensitivity,
0.50 mV.
Ventricular Amplitude, 7.5 V; Pulse width, 0.40 ms; Sensitivity,
2.80 mV.
Rate Drop Response and Detection Type, Both; Intervention
Rate, 70 ppm; Intervention Duration, 15 min; Detection Beats,
1 beat; Drop Rate, 40 ppm; Drop Size, 15 bpm.
As for the pacemaker interrogation data at 1 year after
implantation, the average battery longevity was 13 years (range,
11–14.5 years), which was longer than that with the ordinary
setting. The percent rates of total pacing were as follows: AS-VS,
99.7%; AS-VP, 0.3%; AP-VS, 0%; AP-VP, 0%.
The activity of the pacemaker was assessed using a simulator
system programmed to function in the same way as the patient’s
pacemaker. The patient was thought to have encountered three
patterns of bradyarrhythmia (sinus arrest, atrioventricular block,
or both) after the normal sinus rhythm of 60 bpm. Firstly, when
the sinus arrest occurred, the pacemaker paced the atrium at
1714 ms (the lower rate pacing interval) after previous atrialsensing as AAI 35. At the same time, the RDR was activated, and
the subsequent beats were paced as DDD 70 (Fig. 3A). Secondly,
when the atrioventricular block occurred, the MVP was activated.
The ventricular back-up pacing (VB1) began 1794 ms (the lower
rate pacing interval plus 80 ms) after the previous atrial sensing.
The same ventricular pacing was repeated (VB2). Then, the RDR
was activated, and the subsequent beats were atrioventricular
sequential pacing as DDD 70 (Fig. 3B). Finally, when the sinus
arrest and the atrioventricular block occurred simultaneously, the
atrium was paced 1714 ms after the previous atrial sensing, and
then RDR was activated. Subsequent ventricular sensing was
absent because of the atrioventricular block. The pacemaker
underwent ventricular backup pacing (VB) 1784 ms after the
previous atrial pacing, and then DDD 70 pacing followed as RDR
(Fig. 3C). Therefore, the RDR is activated because of sinus
dysfunction, when the sinus heart rate drops more than 15 bpm
and the heart rate is lower than 40 ppm. Furthermore, the RDR is
also activated when the pacemaker undergoes lower back-up
pacing. The MVP was activated because of atrioventricular
dysfunction. When the sinus arrest occurs ﬁrst, the RDR is
activated before the MVP. On the other hand, when atrioventri-
cular block occurs, the MVP is activated ﬁrst. If the patient’s heart
rate is below the lower rate of the pacemaker setting, ventricular
back-up pacing is activated and the RDR is activated next.
In addition, since epinephrine was effective during PEA, the
patient and her family were given a full explanation on how to
administer subcutaneous injections of EpiPens (Mylan Inc.,
Canonsburg, PA, USA) when needed. However, self-injections of
epinephrine remain controversial. The patient was instructed to
change her eating habits and to eat less. She was then discharged.
The family was advised to become familiar with the use of chest
compression and the automated external deﬁbrillator (AED) in
case of cardiopulmonary arrest. Drug therapy appears to have
been successful, and there has been no recurrence in the year and
a half since the patient was discharged from the hospital.3. Discussion
Variant angina was described by Prinzmetal et al. in 1959 [1].
It can involve serious arrhythmias such as ventricular tachycardia,
ventricular ﬁbrillation, and atrioventricular block, and patients
are particularly susceptible to sudden cardiac death in such cases
[2,3]. Coronary spastic angina without any signiﬁcant coronary
artery constriction responds well to drug therapy with calcium
blockers and has a favorable prognosis [4]. However, in a long-
term observational study, angina recurred despite the use of oral
calcium blockers, with a 3.2% incidence of sudden cardiac death
and a 6.5% incidence of acute myocardial infarction over a period
of 89 months [5]. Although signiﬁcant coronary stenosis is a risk
factor for acute myocardial infarction, it does not affect the
development of fatal arrhythmias [6]. Smoking is the only clear
risk factor for coronary artery spasms [7]. Therefore, an important
clinical issue is the treatment of coronary spastic angina that
recurs despite proactive drug therapy with calcium blockers,
long-acting nitrates, and nicorandil, as well as smoking cessation
and management of obesity, hypertension, impaired glucose
tolerance, and abnormal lipids as recommended in the current
guidelines [8]. This is of major interest, particularly in Japanese
patients who experience coronary artery spasms more
frequently [9].
Implantable cardioverter deﬁbrillators (ICDs) were reportedly
effective in patients who developed ventricular ﬁbrillation despite
maximal drug therapy [10]. However, the Japanese guidelines for
coronary spastic angina state that ICDs should only be considered
in refractory cases, and there is still no consensus on this
Fig. 3. Pacemaker ECG on the simulator system The patient was thought to be in normal sinus rhythm of 60 bpm before bradyarrhythmia occurred. (A) When the sinus
arrest occurred, the pacemaker paced the atrium at 1714 ms (the lower rate pacing interval) after previous atrial sensing as AAI 35. At the same time, the RDR was
activated, and the subsequent beats were paced as DDD 70. (B) When the atrioventricular block occurred, MVP was activated. The ventricular back-up pacing (VB1) started
1794 ms (the lower rate pacing interval plus 80 ms) after the previous atrial sensing. The same ventricular pacing was repeated (VB2). Then, the RDR was activated, and the
subsequent beats were atrioventricular sequential pacing as DDD 70. (C) When the sinus arrest and the atrioventricular block occurred simultaneously, the atrium was
paced 1714 ms after the previous atrial sensing, and then RDR was activated. The subsequent ventricular sensing was absent because of the atrioventricular block. The
pacemaker underwent ventricular backup pacing (VB) 1784 ms after the previous atrial pacing, and then DDD 70 pacing followed as RDR., RDR: rate drop response, MVP:
managed ventricular pacing, VB: ventricular back up pacing.
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speciﬁed for PEA or complete atrioventricular block in the
absence of ventricular tachycardia or ventricular ﬁbrillation [8].
In previous reports, drug therapy in patients with resuscitated
PEA resulted in favorable progress [11] and a DDD pacemaker was
implanted in a patient with complete atrioventricular block and
non-sustained ventricular tachycardia [12].
In the present case, cardiopulmonary arrest was caused by PEA
and bradycardia, not ventricular ﬁbrillation or ventricular tachy-
cardia. Therefore, the present patient’s condition was not amen-
able to electrical deﬁbrillation, and pacemaker therapy was
selected instead. The pacemaker settings for pacemaker therapy
also required some ingenuity. The maximum ventricular output
was set at 7.5 V because settings of longer duration could
potentially result in an increase in the pacing threshold [13].
However, a rate drop response (RDR) setting was selected to
ensure efﬁcient pacing only when needed because ventricular
pacing during normal conditions shortens battery life. In this case,
the pacemaker was set to ensure pacing at a high heart rate
(70 ppm) when the heart rate fell to r40 bpm or there was a
sudden decrease in the heart rate of more than 15 bpm. The
pacemaker used in this case was selected because we felt that itcould provide pacing therapy suitable for this patient’s condition.
Commercially available ICD devices are not capable of RDR
settings, and back-up pacing is the only available setting for brady
pacing. Pacing can therefore be done only at the lowest set heart
rate even during attacks. The selection of settings that anticipate
pacing at a higher heart rate during attacks leads to more frequent
pacing when the heart rate is lower during normal conditions, and
may result in pacing discomfort and battery depletion. However,
pacing stimulation in ischemic regions runs the risk of provoking
serious arrhythmias such as ventricular ﬁbrillation [13], and
concomitant ICD is therefore more desirable in that regard.
Chest compression and epinephrine are effective for PEA,
whereas electrical deﬁbrillation is not. Medium voltage therapy
(MVT) has recently been attempted, where electrical stimulation
by a cardiac device during ventricular ﬁbrillation or PEA induces
skeletal muscle contractions and maintains coronary blood ﬂow
in the same manner as chest compression [14,15]. Although this
technique has not yet been put to practical use, it would appear to
be well suited to cases such as the present one.
We decided not to use an ICD implant because of the absence
of ventricular ﬁbrillation and ventricular tachycardia in this case,
and because more complicated pacemaker settings could not be
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ventricular ﬁbrillation and ventricular tachycardia may develop
in the natural course of the disease or as a result of fatal
arrhythmias induced by pacing after the use of adrenaline, in
which case electrical deﬁbrillation may be necessary.
In focal coronary spastic angina, intravascular ultrasound was
reported to detect intima–media complex thickening and an
increased sonolucent zone [16,17], and OCT can detect intimal
thickening with low lipid and calcium deposits [18], which are
believed to reﬂect neointimal hyperplasia subsequent to intimal
disorders found on histopathology [19]. The OCT ﬁndings in the
present case were similar. Although stenting is an option for local
stenotic lesions following continued treatment with calcium
blockers for refractory coronary spastic angina [20], its use
appears to be limited in cases of multiple vessel spasms, as in
the present case.4. Conclusion
Drug therapy using calcium blockers is a fundamentally
important strategy for treating coronary spastic angina. However,
in cases where atrioventricular block with advanced ischemia
cannot be controlled with drugs alone, drug therapy can never-
theless be expected to have some effect until the vicious cycle
from bradycardia to worsening hemodynamics can be averted
with the support of pacing therapy and until drugs such as
epinephrine and nitroglycerin can take effect. Although not
currently available commercially, a cardiac device combining
RDR pacing function, ICD function for when ventricular ﬁbrilla-
tion develops, and MVT function for PEA would be ideal.Conﬂict of interest
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